The serotonin syndrome.

The serotonin syndrome is a potentially life-threatening drug reaction that may result from therapeutic medication use, self-poisoning, or interactions between drugs.

[1]  Jürgen Gallinat,et al.  The serotonin syndrome scale: first results on validity , 1998, European Archives of Psychiatry and Clinical Neuroscience.

[2]  L. Baxter,et al.  Current concepts. Neuroleptic malignant syndrome. , 1985, The New England journal of medicine.

[3]  L. Lynd,et al.  Sumatriptan Contraindications and the Serotonin Syndrome , 1998, The Annals of pharmacotherapy.

[4]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[5]  G. Isbister.  Comment: Serotonin Syndrome, Mydriasis, and Cyproheptadine , 2001, The Annals of pharmacotherapy.

[6]  P. Gillman.  Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. , 1997, Medical Journal of Australia.

[7]  T. Sharp,et al.  Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: Microdialysis studies in the awake and anaesthetized rat , 1994, Neuropharmacology.

[8]  J. Levenson.  Neuroleptic malignant syndrome. , 2007, The American journal of psychiatry.

[9]  F. Mastaglia,et al.  Neuroleptic malignant syndrome , 1984, The Medical journal of Australia.

[10]  J. Hick,et al.  Metabolic acidosis in restraint-associated cardiac arrest: a case series. , 1999, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[11]  D A Asch,et al.  The Libby Zion case. One step forward or two steps backward? , 1988, The New England journal of medicine.

[12]  S. Kapur,et al.  Cyproheptadine: a potent in vivo serotonin antagonist. , 1997, The American journal of psychiatry.

[13]  R. Baloh,et al.  Myoclonus and ocular oscillations induced by L‐tryptophan , 1982, Annals of neurology.

[14]  Y. Kaneda,et al.  Serotonin syndrome - 'potential' role of the CYP2D6 genetic polymorphism in Asians. , 2002, The international journal of neuropsychopharmacology.

[15]  C. Hiemke,et al.  Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. , 2002, Journal of clinical psychopharmacology.

[16]  C. D. Lee,et al.  Serotonin Syndrome in a Child Associated with Erythromycin and Sertraline , 1999, Pharmacotherapy.

[17]  M. Z. Wincor,et al.  Possible serotonin syndrome in association with 5-HT(3) antagonist agents. , 2001, Psychosomatics.

[18]  J. Warner,et al.  Serotonin syndrome: potentially fatal but difficult to recognize. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.

[19]  S. Kato,et al.  Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. , 2004, Pharmacopsychiatry.

[20]  R. Mann,et al.  Antidepressants and the serotonin syndrome in general practice. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.

[21]  E Ernst,et al.  Interactions between herbal medicines and prescribed drugs: a systematic review. , 2001, Drugs.

[22]  I. Whyte,et al.  Serotonin toxicity and malignant hyperthermia: role of 5-HT2 receptors. , 2002, British journal of anaesthesia.

[23]  Theo Meert,et al.  Functional study of rat 5‐HT2A receptors using antisense oligonucleotides , 2003, Journal of neurochemistry.

[24]  L. S. Mauro,et al.  Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. , 1989, Clinical pharmacy.

[25]  I. Whyte,et al.  Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? , 2001, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[26]  B. Marston,et al.  Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine , 2001, AIDS.

[27]  M. Fink,et al.  Toxic Serotonin Syndrome or Neuroleptic Malignant Syndrome? , 1996, Pharmacopsychiatry.

[28]  S. Fahn,et al.  Increase in brain serotonin produced by bromocryptine , 1975, Neuroscience Letters.

[29]  Y. Kaneda,et al.  The serotonin syndrome: investigation using the Japanese version of the Serotonin Syndrome Scale , 2001, Psychiatry Research.

[30]  S. Giese,et al.  Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl. , 2001, Plastic and Reconstructive Surgery.

[31]  R. Lappin,et al.  Treatment of the serotonin syndrome with cyproheptadine. , 1994, The New England journal of medicine.

[32]  K. Nisijima,et al.  Potent serotonin (5-HT)2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome , 2001, Brain Research.

[33]  Beverley McNeil,et al.  Malignant Hyperthermia , 2005, Springer US.

[34]  Philip B. Mitchell,et al.  Drug Interactions of Clinical Significance with Selective Serotonin Reuptake Inhibitors , 1997, Drug safety.

[35]  S. Kato,et al.  Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome , 2003, Neurochemistry International.

[36]  P. Gillman.  The serotonin syndrome and its treatment , 1999, Journal of psychopharmacology.

[37]  T. Litovitz,et al.  1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. , 2000, The American journal of emergency medicine.

[38]  D. Sibbritt,et al.  The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. , 2003, QJM : monthly journal of the Association of Physicians.

[39]  J. Callaway,et al.  Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. , 1998, Journal of psychoactive drugs.

[40]  A. Sjoerdsma,et al.  Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor , 1960, Neurology.

[41]  U. Ekblad,et al.  Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. , 2003, Archives of general psychiatry.

[42]  H. Sternbach.  The serotonin syndrome. , 1991, The American journal of psychiatry.

[43]  G McKay,et al.  PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. , 1997, The American journal of psychiatry.

[44]  A. Parrott,et al.  Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity , 2002, Pharmacology Biochemistry and Behavior.

[45]  F. LoVecchio,et al.  Serotonin syndrome in a child after a single dose of fluvoxamine. , 1999, Annals of emergency medicine.

[46]  T. Balcezak,et al.  Serotonin Syndrome Presentation of 2 Cases and Review of the Literature , 2000, Medicine.

[47]  S. R. Rose,et al.  2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. , 2003, The American journal of emergency medicine.

[48]  J. Jankovic,et al.  Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. , 1996, Clinical neuropharmacology.

[49]  S. Bowe,et al.  Relative Toxicity of Selective Serotonin Reuptake Inhibitors (SSRIs) in Overdose , 2004, Journal of toxicology. Clinical toxicology.